Atlas Trials

Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation

Clinical trial NCT03989089 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03989089
Sponsor
University of Malaya
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-Negative Breast Cancer
Start date
2020-07-03
Primary completion
2025-12-01
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.